CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Yunhui Cheng et al.|Cell Reports Medicine|2024Cited by 28
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancerJie Luo, Arul M. Chinnaiyan|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 10